Crispr Therapeutics (NASDAQ:CRSP) had its target price boosted by Barclays from $29.00 to $59.00 in a research report released on Wednesday, March 7th. They currently have an overweight rating on the stock.
Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research report on Thursday, January 25th. Oppenheimer initiated coverage on Crispr Therapeutics in a research note on Thursday, December 7th. They issued a hold rating for the company. SunTrust Banks raised Crispr Therapeutics from a hold rating to a buy rating in a research note on Tuesday, January 23rd. BidaskClub raised Crispr Therapeutics from a hold rating to a buy rating in a research note on Thursday, January 4th. Finally, Citigroup boosted their target price on Crispr Therapeutics from $20.00 to $51.00 and gave the stock a neutral rating in a research note on Wednesday, February 28th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Crispr Therapeutics presently has an average rating of Buy and an average target price of $53.53.
Crispr Therapeutics (CRSP) traded up $1.00 during mid-day trading on Wednesday, reaching $57.51. 1,207,568 shares of the company’s stock were exchanged, compared to its average volume of 1,110,491. Crispr Therapeutics has a 1 year low of $13.50 and a 1 year high of $61.24. The company has a market capitalization of $2,590.00 and a PE ratio of -36.87.
In related news, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, January 5th. The shares were acquired at an average cost of $22.75 per share, for a total transaction of $11,999,988.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kurt Von Emster sold 37,754 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $26.76, for a total value of $1,010,297.04. The disclosure for this sale can be found here. Insiders sold 298,850 shares of company stock valued at $7,545,365 in the last ninety days. 39.98% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of the business. Farallon Capital Management LLC bought a new position in shares of Crispr Therapeutics during the 4th quarter worth approximately $20,160,000. Franklin Resources Inc. raised its position in shares of Crispr Therapeutics by 8.9% during the fourth quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after purchasing an additional 65,200 shares during the period. Global Thematic Partners LLC raised its position in shares of Crispr Therapeutics by 11.2% during the fourth quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after purchasing an additional 63,611 shares during the period. BlackRock Inc. raised its position in shares of Crispr Therapeutics by 16,623.9% during the fourth quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock worth $12,974,000 after purchasing an additional 549,254 shares during the period. Finally, Opaleye Management Inc. acquired a new position in shares of Crispr Therapeutics during the fourth quarter worth approximately $6,597,000. Hedge funds and other institutional investors own 27.29% of the company’s stock.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.